Rebinyn or Refixia Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to clinical development of recombinant FIX therapies, rising diagnosis rates of hemophilia B, early adoption of long-acting factor products, improved access to hemophilia care centers, regulatory approvals for extended half-life biologics.

The growth in the forecast period can be attributed to growing demand for convenient hemophilia management options, expansion of home-based treatment models, increasing investments in next-generation clotting factors, rising focus on improving patient quality of life, advancements in biologic drug engineering. Major trends in the forecast period include increasing adoption of extended half-life clotting factors, rising preference for prophylactic hemophilia treatments, expansion of recombinant factor therapies, growing focus on reducing injection frequency, enhanced patient-centric treatment approaches.

The rising prevalence of hemophilia is expected to drive the growth of the Rebinyn/Refixia market. Hemophilia is an inherited bleeding disorder caused by deficiencies in blood-clotting factors, and its rising prevalence reflects both an increase in diagnosed patients and newly identified cases. Improved genetic testing has led to more accurate and earlier diagnoses, resulting in a growing patient population each year. Rebinyn/Refixia supports this trend as an extended half-life factor IX therapy, enabling patients to manage frequent bleeding episodes with fewer injections, improving treatment adherence and long-term outcomes. For instance, in April 2025, according to Pfizer Inc., the UK hemophilia A and B patient population exceeded 11,800 individuals, highlighting a clinically significant treated population. Therefore, the rising prevalence of hemophilia is driving the Rebinyn/Refixia market.

The growing healthcare expenditure is also expected to propel the Rebinyn/Refixia market. Healthcare expenditure includes the total spending on health services and related activities, driven by factors such as aging populations, chronic diseases, higher service costs, increased demand, technological advancements, rising drug prices, medical inflation, and the ongoing impact of COVID-19. Increased healthcare spending improves access to Rebinyn/Refixia, ensuring better management of hemophilia B through greater affordability and availability. For example, in May 2024, according to the UK Office for National Statistics, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022, while long-term health and social care expenditure increased by 2.8% in real terms in 2022. Therefore, rising healthcare expenditure is driving the Rebinyn/Refixia market.

Major companies in the Rebinyn/Refixia market are focusing on high-dose formulation expansion to improve dosing efficiency for patients requiring higher factor IX levels. High-dose vials, such as 3,000 IU Rebinyn vials, allow for larger single-administration units, reducing infusion frequency and simplifying prophylaxis for patients with moderate to high dosing needs. For instance, in 2023, Novo Nordisk, a Denmark-based biopharmaceutical company, launched the Rebinyn 3,000 IU vial, the highest dose in the Rebinyn portfolio. This launch offered reduced infusion burden for adult patients needing higher prophylactic levels while maintaining the same GlycoPEGylated extended-half-life technology as lower-dose vials. The introduction strengthened therapeutic flexibility and expanded individualized management options in the Rebinyn/Refixia market.

Major companies operating in the rebinyn or refixia market are Novo Nordisk A/S.

North America was the largest region in the rebinyn or refixia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rebinyn or refixia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rebinyn or refixia market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the rebinyn or refixia market by increasing costs of imported biologic manufacturing inputs, recombinant protein production equipment, cold storage systems, and specialized packaging materials. Treatment providers in North America and Europe are most affected due to reliance on imported bioprocessing components, while emerging markets face higher therapy acquisition costs. These tariffs are contributing to increased treatment expenses and supply chain complexity. However, they are also driving investment in domestic biologics manufacturing, regional fill-finish capabilities, and long-term supply security for hemophilia therapies.

The rebinyn or refixia market research report is one of a series of new reports that provides rebinyn or refixia market statistics, including rebinyn or refixia industry global market size, regional shares, competitors with a rebinyn or refixia market share, detailed rebinyn or refixia market segments, market trends and opportunities, and any further data you may need to thrive in the rebinyn or refixia industry. This rebinyn or refixia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rebinyn, also known as Refixia in certain regions, is a long-acting recombinant factor IX (FIX) therapy used to treat and prevent bleeding in patients with hemophilia B. It is designed with an extended half-life to reduce the frequency of injections needed for effective management. Rebinyn replaces the deficient FIX protein in hemophilia B patients, enabling proper blood clotting. It is used for routine prophylaxis, on-demand treatment, and managing bleeding during surgical procedures, providing improved convenience and quality of life.

The main formulations of Rebinyn or Refixia are intravenous injection and lyophilized powder. Intravenous injection delivers the medication directly into a vein for rapid absorption into the bloodstream. These formulations are indicated for hemophilia B management, prevention of bleeding episodes, and on-demand bleeding control across pediatric, adult, and geriatric patients. The primary users include hospitals, clinics, and homecare settings, with distribution through hospital pharmacies, retail pharmacies, and online pharmacies.

The rebinyn or refixia market consists of sales of recombinant factor IX (FIX) products and blood clotting replacement solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.